200+ SPEAKERS  |  150+ SESSIONS  |  20+ WORKSHOPS  |  6 STAGES

Where pharma comes to life


Keynote Sessions

The theme of Barcelona 2020 is ‘Where Pharma Comes to Life’. This phrase implies an evolution from our chemical, product-centric, shareholder-oriented corporations into to a flourishing ecosystem of biological and precision solutions with a comprehensive, digitally-enhanced, outcomes-oriented ecosystem. Truly we are redefining the nature of what a pharma company is.

The 4 key areas:

  • Authentic Leadership: ensure integrity and accuracy in decision-making and portfolio design. Gain healthcare’s trust through medically-driven content, customer innovation and holistic patient solutions
  • New ways to reach commercial goals: turn HCPs into influencers and inspire patient champions. Use content, education, empowerment and open innovation to harness external relationships
  • From drugs to treatments: use cloud platforms, data insights and joint ventures with startups to generate a new suite of digital products, value-added services and cell/gene therapies. Go from druggable & reactive to curable & preventative
  • Digitise evidence: prepare a superior mix of virtual clinical trials and regulatory-grade RWE to gain authorisation, widen access, boost launch and drive patient outcomes

Sven Dethlefs EVP, Global Marketing & Portfolio Teva

Alberto Martinez CEO Mundipharma

Chris Round EVP, Head of International Operations & Global Core Franchises Merck

Kris Sterkens Company Group Chairman, Janssen EMEA Janssen

Jeffrey Wren EVP, Neurology Patient Value Head UCB

Badhri Srinivasan Head, Global Development Operations Novartis

Klaus Dugi EVP, Chief Medical Officer Ferring

Colin Sims EVP, Strategy Kyowa Kirin International

Camilla Harder Hartvig SVP, International Business Alexion

Niko Andre Head of Global Medical Affairs Roche

Jassi Chadha CEO Axtria

David Meek CEO Ipsen

Bertrand Bodson Chief Digital Officer, Member of the Executive Board Novartis

Steve Miller EVP, Chief Clinical Officer Cigna


Let the health entrepreneurs show you how

  • See what the most innovative health start-ups are doing to create value for patients and healthcare – then be the judge to crown the winner!
  • The following companies will deliver an elevator pitch during the plenary sessions, with the winner crowned on Day 3 Keynote Stage

A Reuters News-led Panel Reuters

Searching for a drug pricing solution: Ideas from around the globe

The panel will discuss how to balance medical advances with affordability*

Moderators: Axel Threlfall Editor-at-Large Reuters

Caroline Humer Correspondent Reuters

Panellists: Steve Miller EVP, Chief Clinical Officer Cigna

Peter Bach Director Memorial Sloan Kettering Cancer Center

Further panellists to be released next month

*Reuters editorial operates independently from Reuters commercial operations.

Accomplish cultural transformation


Case Study: How to initiate an effective turnaround plan that cascades through your business

  • Identify the obstacles you face when changing your core business model and how to overcome them
  • See the process Allergopharma used to identify the best of commercial pharma which it wanted to adopt – and the areas that were avoided

Philipp Maerz CEO Allergopharma


Create a holistic customer experience: break down silos to harness the combined power of commercial capabilities and medical authenticity

  • See the whole customer journey by aligning commercial and medical teams under one overarching engagement strategy, across all field and digital initiatives
  • Why education principles and disease led strategy are crucial to successful collaboration
  • Redefine “a good customer relationship” by leveraging combined insights and capabilities without tarnishing the valued authenticity of an independent medical affairs

Heather Moses Global Marketing Leader & Head of Medical Affairs Roche

Gareth Worthington Director, Global Scientific Content, Oncology Team Lead MSD


What culture and capability changes are required to accelerate digital adoption throughout your organisation

  • Encourage greater digital implementation amongst laggard teams by using metrics and KPIs that more tangibly demonstrate long-term impact
  • Create a global strategy that evolves to meet local affiliate constraints and specific customer requirements, whilst reducing duplication of effort

Florent Edouard SVP, Global Head of Commercial Excellence & Customer Engagement Grünenthal

Abel Archundia SVP, Global Head of IT & Digital Transformation Bayer


Google’s challenge to pharma: a patient-centric approach to insights and data

  • Use insights garnered around your consumer as the central pillar of your patient-centric approach
  • Create a better understanding of the health-tech ecosystem to satisfy your marketing needs

Stefani Klaskow Head of Industry, Healthcare Google

Beyond traditional marketing


Case Study: Almirall’s Digital Garden that partners with start-ups to innovate together

  • Provide start-ups with the nutrients they need to grow into the next digital disruptor
  • Co-create cutting edge digital solutions when you provide pioneering start-ups leveraging pharma expertise
  • Learn how you can streamline your own operations through symbiotic sharing of information and processes

Francesca Wuttke Chief Digital Officer Almirall


Case Study: Beyond the medicine: Co-creating solutions that meet real world patient and HCP needs

  • Explore 3 projects from Roche Innovation Lab and hear about the journey behind each project from first interaction to final solutions
  • Understand how each solution delivers value to the users by getting insights in user feedback and Roche’s learnings

Jonas Kierkegaard Head of Innovation Lab Roche


Empower commercial decision-making: Bring data from every interaction together

  • Define your digital investment strategy by creating a continuous feedback loop of engagement activity
  • Give reps and marketing strategists the advantage with a backbone infrastructure that links together separate systems, spreading of insights and data throughout the business

Renaud Sermondade VP, Global Head of Insights and Analytics Sanofi


Case Study: Why disease strategy trumps brand strategy

  • See the enormous patient outcome and reputational benefits of focusing on improving therapeutic area care alongside drug provision
  • Explore the long-term business case for forgetting about the brand


Create a social strategy that delivers across all age populations

  • Across demographics HCPs and patients are changing how they are connecting and self-educating
  • Understand your audience to create connections
  • See how a mixed social influencer strategy with advocacy partnerships helps to scale outreach


Closed-loop marketing: An integrated channel approach for consistent success

  • Ensure marketing, IT and external alignment to make sure capabilities are there to back-up marketing innovations
  • Make informed channel and content selection decisions by creating a backbone infrastructure that allows data flow across the company

Andreas Dach Digital & Multi-Channel Lead Eli Lilly

Deliver personalised CX


Deliver a personalised customer experience through marketing automation

  • Use marketing automation to create memorable customer journeys through the most relevant channels
  • Further improve CX by gathering and analysing data seamlessly through an integrated platform

Christian Scheuer VP, Global Commercial Affairs & Excellence LEO Pharma


Case Study: Why disease strategy trumps brand strategy

  • See the enormous patient outcome and reputational benefits of focusing on improving therapeutic area care alongside drug provision
  • Explore the long-term business case for forgetting about the brand


Case Study: Walk in your customer’s shoes: understand every step of the customer journey to provide personalised CX

  • Build a complete picture of your customer by tracking all interactions, not just those with your own brands
  • Focus on the motives of your physicians’ actions to ensure you provide the service they need most effectively

Steve Skyrme Global Lead, Customer Experience, Oncology Pfizer


Case Study: Effectively mix content using AI

  • Understand why and how GSK have invested in AI and Machine Learning
  • Glimpse the future of pharma where AI is central to every operation

Denise Dewar Digital Hub Director, Europe GSK


Case Study: Adopt human-centered design. Achieve optimal customer experience.

  • Understand how a “human-first” cultural ethos was implemented, and practicalities of maintaining this whilst scaling up
  • Achieve sky high retention rates with an online CX combining behavioural science, with digital and traditional support methods
  • Digital isn't always right: Examples of how this approach led to a variety of patient and HCP solutions driven by customer understanding, not technological availability


Enhance the capabilities of your customer facing team using AI insights

  • Design a comprehensive ‘customer persona’ profile to fully understand and meet individual customer need
  • Perfect your omnichannel strategy with quality insights generated through cutting edge AI

Stefano Zagnoni Head of Digital & Innovation Janssen


Differentiate your product with value-added services through user-centric design

  • Learn how to drive adoption by differentiating your value-added programs in an often-saturated environment
  • Design fit-for-purpose services and ensure sustained use by engaging in co-creation with HCPs and/or patients throughout service development

The multichannel fieldforce


Create an adaptive field force to meet customer expectations in the digital world

  • Find balance between virtual engagements and infield activity to ensure relationship building remains personal
  • Optimise rep engagement by ensuring the value of digital capabilities is clearly demonstrated, fostering greater transformation
  • Define the evolving role of the rep in the era of increased medical engagement, whilst increasing collaboration to create a seamless customer experience

Pieter De Muynck Global Marketing Leader - Global Commercial Strategy Organization Janssen

Rodney Smith VP, Head of Medical Affairs Europe Daiichi Sankyo


Commercial & sales interactive roundtable discussions

  • Data driven commercial decision making
  • The customer-centric field force
  • Disease strategy over brand strategy
  • Successful execution of global strategy on the local level
  • Measuring customer experience and value provision
  • Aligning medical and commercial aims and methods


Digital & marketing interactive roundtable discussions

  • Product differentiation through value-added services
  • Expand and integrate your channels to better connect with HCPs
  • Prove the value of digital and change your internal culture
  • Closed loop marketing of the future
  • Use big data to personalize customer experience

Berfu Tavelli Digital Initiatives Manager Sanofi

Nuno Rodrigues Digital & Multichannel Manager Roche

Organisational empowerment


Get your organisation on the same page

  • Success starts at home – how to put in place strong internal networks that make external operations seamless
  • Why you need to determine what patient centricity is to your organisation and make sure that culture and strategy is being infused across all functions

Edward Trott Chief Patient Officer Ferring


Make patient engagement your new normal

  • Consistently be meeting best practice guidelines for systematic, meaningful patient engagement
  • Stay ahead of the game: Demand engagement to keep your competitive advantage as regulators signal a shift to making it expected
  • The Legal & Compensation Conundrum: How to derive fair market value for your patient network and set reasonable legal agreements to keep them coming back and contributing

Nicholas Brooke Executive Director Patient Focused Medicine Development


Panel: No trust, no data? No pharma. Create a patient data research opportunity through education and collaboration #DataSavesLives

  • Case Study: How the new #DataSavesLives EPF initiative is improving patient perspectives on data use by providing complex information in an understandable and accessible way
  • Understand the importance of trust in improving data sharing attitudes as patient ownership increases

Nicola Bedlington Special Advisor European Patients Forum

Propel patient-led deisgn


Know your audience: develop tools that patients can understand

  • Drastically improve your educational tools by engaging the right patients to establish where their knowledge gaps are and how to fill them
  • The simpler, the better: ease HCPs' workload by developing materials that make delivery seamless and help patients articulate their needs

Christina Claussen Director, Alliance Management & Patient Relations Pfizer

Eva Schumacher-Wulf Patient Advocate & Editor-In-Chief Mamma Mia! Magazine


Challenge the ‘old pharma’ mindset with evidence-based outcomes

  • Empower the patients voice in-house and convince all functions of its value by developing measurable insights
  • Break down silos to swiftly incorporate the patient’s perspective when developing new services

Geoff Rollason Patient Experience & Service Director - Oncology Pfizer


If you think you’re patient-centric, you’re probably only halfway there

  • Case Study: How Novo Nordisk developed next generation support programmes by engaging their patient partners to identify and then solve critical unmet needs for those with diabetes
  • Learn from your mistakes: An honest assessment of how to identify flaws in your frameworks when approaching patient support in different socio-economic, cultural and healthcare systems

Jenna Copeland Kristensen Global Director, Patient Support Programmes Novo Nordisk

Insight driven patient-centricity


Case Study: Syntropy – safeguard data ownership and foster cancer-care and research through an advanced analytics platform

  • Build a network of researchers and organisations to drive scientific discovery and enable better care for patients
  • Waiting for more details on case study

Steven Hildemann SVP, Chief Bio-Ethics & Employee Health Merck


Not just lip service but real results

  • Examine why AstraZeneca created a strategy for growth by connecting innovation to patient centricity
  • Case Study: Discover-NOW; how this new collaborative innovation-hub will gather real world evidence to better monitor and manage patients with Type-2 Diabetes

Adam Higgins Senior Director, Digital Health, Patient & Value Solutions AstraZeneca


From digital health to DTx, how to gain adoption!

  • Don’t start with a solution, start with a problem
  • Focusing on patient needs alone is not enough to ensure widespread, impactful use
  • Consider the needs of all stakeholders to develop a core adoptable solution that can be scaled
  • Examples and lessons learned from real deployments

Jim O’Donoghue President S3 Connected Health


Case Study: achieve commercial excellence with a patient-centric framework to pioneer patient access

  • Streamline your commercial strategy by holistically assessing and addressing unmet customer needs
  • Boost efficiency with Sandoz’s framework introducing integrated marketing and sales agenda

Alexey Cherchago Head of Sales Excellence Europe Sandoz

Collaboration Evolution


The future is collaborative: How open innovation can enable patient-centric research

  • Understand how trust, mutual benefits and transparency can truly change the collaboration model
  • Explore how to engage a network of scientifically minded patients who can drive a new era of open innovation in R&D
  • Deliver patient relevant solutions by bridging the language gap between insights and research activities

Niclas Nilsson Head of R&D Open Innovation LEO Pharma


Partner up: Lessons for long-term collaboration

  • Move past the money; why you need to shift away from a purely transactional relationship if you want to create a true collaboration
  • How to align expectations from the outset to prevent likelihood of problems
  • Trust, transparency and respect – buzzwords or the foundation to better relationships with patients

Andy Powrie-Smith Executive Director, Communications & Partnerships EFPIA


Panel: We all have a shared interest; better healthcare for patients

  • From small through to global organisations; discover what is best practice for engaging patient groups with various capabilities
  • You’re on the frontline, so lead from the front; why those in patient-centric roles must be the patients champion internally
  • The future is now: Understand how to pave the way for a new era of collaboration

Paul Robinson European Lead, Patient Innovation MSD

Olive Fulton Patient & Public Involvement Lead Asthma UK Centre for Applied Research

Vanessa Pott Director, Patient Advocacy & Strategic Partnerships Merck

Isabelle Bocher-Pianka Chief Patient Affairs Officer Ipsen


Patient engagement interactive roundtable discussions

  • Empowering patients
  • Co-creation & patient-led design
  • Increasing adherence
  • Best practice engagement
  • Humanising healthcare

Mary Lynne Van Poelgeest-Pomfret President World Federation for Incontinent Patients - WFIP

Jacob Holst Andersen Head of Public Affairs & Patient Relations AbbVie

Teresa Ferreiro Patient Advocate

Frank Hennemann Patient Advocate

Petra Verdaasdonk Patient Advocate

Ramona Kanters Patient Advocate Open

Christa Overtoom Patient & Family Therapist

Carol Munt Patient Partner & Advocate

Diversification, leadership and authenticity: Medical affairs beyond 2020


Driving value – the evolving strategic role of Medical Affairs

  • Connect science, clinical outcomes and patient value to build a future-fit Medical Affairs function
  • Build a positive reputation and drive scientific exchange with an ever-expanding external stakeholder community
  • Identify, optimize and integrate external insights to inform medical/corporate strategy and enhance value delivery
  • Deliver strategic impact for the C-Suite as a business savvy and agile partner

Charlotte Kremer EVP, Head of Medical Affairs Astellas


Future-proof medical affairs: How to evolve into an agile, customer-driven function

  • Medical Governance frameworks to structure around the customer, internal and external, to co-create and present value
  • Excel in an algorithm and data driven healthcare decision-making system

Michael Zaiac Head of Medical Affairs, Oncology, Europe Novartis


Empower your medical field force and fulfil stakeholder need

  • Don’t limit your MSLs to HCPs: define their new role on the frontline of pharma’s field force expanding across patient groups and market access authorities
  • MSLs aren’t superhuman: help them realise their full potential with a clear overall field-team strategy, whilst building capabilities in key business operational and soft skills
  • Ensure MSLs are not tongue-tied with a defined company compliance and medical governance framework

Emma Booth Director, Head of Medical Strategy and Operations Amgen


Panel: Conduct your evidence symphony - a new paradigm to align cross-company evidence generation around outcomes

  • Better identify study gaps and requirements with Medical becoming the transceiver of scientific information across RWE studies and clinical trials
  • Why every company should centralise company evidence generation strategy to be led by Medical Affairs

Niko Andre Head of Global Medical Affairs Roche

Klaus Dugi EVP, Chief Medical Officer Ferring

Michael Seewald VP, Global Head, Real World Evidence Novartis

Pol Vandenbroucke SVP, Chief Medical Officer, Hospital Business Unit Pfizer

Charlotte Kremer EVP, Head of Medical Affairs Astellas


Achieve 360° measurement into the patient and physician impact of medical activities

  • Cost effective ways to measure and understand customer behaviour change
  • Adopt non-traditional metrics that more accurately represent medical’s unquantifiable and non-commercial value


Medical affairs leadership roundtable discussions

  • Structure Medical Affairs to facilitate growing role diversification and leadership position
  • Increasing physician trust in RWE
  • Medical Governance frameworks to ensure medical and marketing compliance as collaboration increases
  • Enhance HCP engagement with digital implementation into Medical engagement strategy

Drive medical authenticity with digital


Enlighten medical decision-making with an integrated insights system

  • How to ensure real time insight is at the heart of your strategic decisions
  • Locate the insight source and turn insights into action for short and long term value to the business, HCP and patient
  • Ensure systems are purpose led, not technology – choosing the right system your needs

Victoria Ho Director, MSL Excellence EU/RoW Jazz Pharmacauticals


Multi-case study session: Drive medical excellence with novel digital application

  • Maximise limited physician interaction time with data informed field force decision-making and content generation
  • Create new key stakeholder engagement opportunities with a focus on push over pull, using new technologies to catalyse HCP interactions across the customer journey
  • Provide medical education through virtual channels to increase efficiencies and reduce customer burden

Jose Antonio Buron Vidal VP, Medical Affairs Europe Janssen

Mark Johnson Director of Digital Engagements, Medical GSK

The real-world data jigsaw: Let’s put the pieces together


Real-world data as the trust catalyst for partnerships between pharma and healthcare systems

  • How RWD has played a critical role in establishing trusted partnerships
  • How to achieve better patient outcomes through RWE driven collaborations
  • Why RWD is the key to a performance based system, driven by real-time real-world insights

Michael Seewald VP, Global Head, Real World Evidence Novartis


Case Study: Bridging the divide between US and EU common data models

  • How the CPRD are translating UK patient records into the FDAs Sentinel Programme and IMI EHDEN’s common data models to extend pharmacovigilance across continents

Janet Valentine Director of the CPRD CPRD


Case study: Aligning regulatory and HTA decision-making around RWE assessment - CAT Initiative

Tarry Ahuja RWE Lead & Manager, Policy & Product Development Canadian Agency for Drugs & Technology in Health


HARMONY: Enhancing patient care and R&D decision-making through integration of pan EU haematological data

  • How the IMI HARMONY Consortium overcame data anonymisation, harmonisation and privacy challenges to integrate clinical, genomic and registry data into a single Big Data Platform
  • The reality and future promise of Big Data approaches to unanswered medical questions
  • Future expansion through greater RWD integration to enable synthetic control armed trials, expanded patient representation and hypothesis generation to support new study design

Pam Bacon Executive Director, Global Medical Affairs Celgene


Panel: Amplify research opportunities with integrated RWD systems – learning from IMI’s BD4BO

  • How IMI’s EHDEN project is progressing in building a federated data networking across Europe using a common model, with key achievements and objectives
  • How the PIONEER initiative is creating a standardised data platform for prostate cancer, combining clinical and RWD sources, to enable greater therapeutic area research capabilities
  • Why standardisation is key in a world of linkage and AI/ML capabilities, and how these different approaches work in unison
  • Ensure data availability - approaches to increasing data holder’s willingness to share centralised data

Nigel Hughes Scientific Director Janssen


The data privacy and sovereignty focus group

  • How to access and combine new datasets, encourage data sharing and cloud adoption whilst ensuring patient privacy remains priority
  • Reaching a common ground on GDPR interpretation – including the latest EU commission guidance and framework on data sharing
  • Discuss concepts like “Fair Trade Data” driving greater public ownership and control over their own data assets

Aida Ponce Privacy Officer & Senior Researcher ETUI

Richard Stephens Patient Advocate NCRI

The RWE Regulatory Revolution


Expand your RWE horizon: The regulatory precedent for RWE submission

  • Overview of the latest guidance and legislation such as the FDA’s RWE Framework, EMA’s recent Regulatory Science to 2025 and the MHRA’s Early Access to Medicines Scheme - plus notable global perspectives
  • The core principles behind making RWD usable in regulatory submission

Giuseppe Rosano Member CVWP EMA


Case study: Achieve RWE-only regulatory label expansion

  • Why an RWE-only submission strategy meant lower costs and overall faster approval process in comparison to the traditional study process
  • Agree on study design and methodology with early regulatory engagement
  • How to ensure regulatory-standard RWD - the steps taken to ensure data sources were appropriate and of high quality, ensuring credibility

Chris Boone VP, Global Medical Epidemiology & Big Data Analysis Pfizer


How to win friends and influence trial design

  • Use of RWE to enhance clinical development, from clinical trial design to determining additional evidence needs
  • Successful (and unsuccessful) examples of using RWE to influence early decision making and some practical examples of how to overcome these challenges
  • The next steps pre-launch RWE application – creating more efficient trials, accelerating the time to decision making and augmenting clinical trials with RWE

Michael Lees Head of Access-Centred Evidence Planning Takeda


Panel: Generate RWE pre-approval to expand access and better inform pricing negotiations

  • Better inform dossier submissions with new forms of evidence, such as comparative efficacy and cost to hospital, not traditionally part of RCT’s scope with concurrent RWE studies
  • Gain internal buy-in by working with regulators to inform evidence collection and use strategy
  • Discuss next steps toward a new development paradigm with normalised RWE generation inclusion and reduced RCT reliance

Anjan Chatterjee VP, Real World Evidence - COE, Epidemiology and Big Data Boehringer Ingelheim

Sam Hariry Head of Clinical Strategy & Operations Novartis

Chris Boone VP, Global Medical Epidemiology & Big Data Analysis Pfizer

Pall Jonsson Associate Director, Science Policy and Research NICE

Viva la market access revolution – systematic change in Europe


The affordability vs productivity conundrum

Jorg Mahlich Head of HEOR Janssen


Foresight into Trump’s unknown: Impact of the US drug pricing crisis in Europe

  • Assessment of pricing implications for the European market access system
  • Update on new, proposed and predicted legislative changes


Panel: HTA alignment – making European market access efficient

  • See the stakeholder engagement process behind the first successful joint HTA appraisals and price negotiations
  • Discuss how to reduce duplication of effort and ensure joint international assessment will translate into patient access on a local level
  • Understand what Common European Assessment models are proposed and how you can engage with their development

Anna Papin di Pompeo President Government Affairs - Europe Merck Group


Market access interactive roundtable sessions

  • Smart ways to evaluate the reimbursement of early stage products – beyond payer dialogue
  • Affordability and developing economies
  • Early engagement with payers: the positives and negatives
  • The increased role of market access in engaging/advocating with patients
  • Innovative pricing solutions: key challenges
  • Ensure payer considerate pipelines - implement market access priorities into early R&D

Raquel Riol Head of Market Access, AMESA Region Sanofi

Lara Pippo Head Market Access, Italy CSL Behring

Adam Kundzewicz Head of Strategic Market Access Initiatives Boehringer Ingelheim

Maximise your data assets – find new insights and create more credible evidence


Rejuvinate your data - use deep learning to improve data asset ROI

  • Find actionable insights to inform research decision-making by using machine/deep learning to rediscover your existing datasets
  • Avoid bias in your algorithms – the need for optimal source data and methodologies


Case Study: Novartis’ AE Brain - AI that predicts adverse events and product complaints from your digital channels

  • Use AI to identify potential safety cases and product technical complaints across your complete digital channel spectrum, including chatbots, CRM notes, social media, apps and email. And its GxP too
  • Scale Xperience: A novel solution to scaling in a global enterprise solving compliance barriers, organisational silos, avoiding AI bias, adoption hurdles and sustainable funding

Abhimanyu Verma Lead, Applied Technology Innovation Novartis

Innovative evidence for innovative access


Creative partnership to bolster post-marketing studies with non-traditional data sources

  • How to work with health systems to cut down manual data input and study resource requirements to allow access to new sources/forms of data such as GP records
  • Combine new data with existing datasets to reconfirm existing evidence Create robust evidence for orphan and rare disease treatments


Use patient-centered evidence to influence market access decision-making

  • Influence HTA and payer decision making by translating qualitative PRO evidence into more traditional value formats
  • Understand how to review QOL, carer and patient feedback, and other patient focused endpoints
  • Explore recent developments in patient engagement framework and PRO submission guidelines when working with the FDA

Stefan Holmstrom Global Head, PRO Excellence & HTA Strategy Astellas


Patients at the heart of cost-effectiveness analysis: NICE policies on measuring quality of life

  • Understand NICE’s policy on measuring and valuing QoL using EQ-5D-5L and what this means for your evidence package requirements
  • Insight into NICE’s support for research in emerging areas such as broader measures of quality of life (‘extending the QALY’) and measuring and valuing quality of life in children

Rosie Lovett Senior Scientifc Advisor NICE

Innovative pricing solutions showcase


Case study: Next generation HTA: How HTx is implementing new assessment methods that support personalised treatment

  • Understand new methodologies that deliver customised information on drug effectiveness to match the complexities of new personalised treatments (e.g. CAR-T)
  • How the H2020 project HTx is fostering greater adoption of new methodologies through alignment of regulators, HTAs, payers, clinicians and industry around the same standards
  • See how RWD can be combined with RCT to demonstrate real-life drug effectiveness

Wim Goettsch Special Advisor HTA; Affiliate Associate Professor International Collaboration in HTA, Universiteit Utrecht ZINL


Panel: Reform or Revolution? Achieve affordable pricing for curative and predictive medicines

  • Learn how existing CAR-T and gene therapy agreements use RWE to demonstrate the long-term value of their treatments, whilst overcoming data quality deficiencies and methodology challenges
  • Discuss how to engage early with authorities to find flexible performance schemes that share risk fairly between both parties
  • Explore proposals on how to measure the long-term healthcare impact of preventive and curative treatments to satisfy HTA assessment

Alexander Natz Secretary General EUCOPE

Martin Price VP, Health Economics, Market Access and Reimbursement, EMEA Janssen

Tamir Singer Head of Commercial Access & Value, Commercial Medicines Directorate NHS England

Wim Goettsch Special Advisor HTA; Affiliate Associate Professor International Collaboration in HTA, Universiteit Utrecht ZINL

The innovation stage


Where is tech innovation bringing real value in healthcare – and how are pharma companies keeping pace?

  • In which areas are new tech advances driving innovation in healthcare? How do pharma companies need to adapt to stay relevant?
  • Discover how strong data analysis is now seen as a core competency and where it can reveal unseen insights to add significant business value
  • Learn how integrating AI, blockchain, VR/AR and other emerging technologies is accelerating productivity and efficiencies across the industry
  • Understand how working with startups can accelerate digital innovation and foster new ways of working for better overall outcomes

Michelle Shogren Director of Innovation - Pharma R&D Clinical Operations Bayer

Ali Abusnina Senior Data Scientist Boehringer Ingelheim BI X Digital Lab


Using AI and blockchain to advance drug discovery & development

  • Find out why combining AI and blockchain can massively shorten times and increase effectiveness in the drug development process
  • Hear why the most valuable data for drug discovery is often hidden in silos or unpublished research and how using the blockchain can counteract this
  • Discover why researchers currently have incentives to hide their work rather than collaborate and how a new paradigm is needed to incentivise all the players in the drug development ecosystem

Gunjan Bhardwaj Founder & CEO Innoplexus


Linking AI with advanced validated digital biomarkers to improve patient outcomes

  • Understand how the development of advanced digital biomarkers enables better measurement, monitoring and management of diseases
  • Discover how enhanced data science techniques are helping to HCPs deliver highly personalized healthcare
  • Learn about the key roles AI and machine learning play in discovering and interpreting complex patterns in enormous data sets to create digital biomarkers

Bert Seegers Chief Business Officer Orikami


Making healthcare provision more intelligent and personal. Is AI the answer?

  • Find out how AI is helping health care providers access vast data sets of potentially life-saving information
  • Hear best practice on what data can be gathered across millions of patient records across multiple geographical locations, and innumerable and sometimes interconnected health conditions
  • See how AI can help detect and analyze large and small trends from the data and make predictions through machine learning that are designed to identify potential health outcomes
  • What’s next? Where does the technology currently fall short and what new insights will we be able to get as the it advances still further


How blockchain technology could reinvent the pharmaceutical supply chain

  • Hear the latest on the Innovative Medicines Initiative Programme “Blockchain Enabled Healthcare”, a consortium approach to establish the use of blockchain in the healthcare industry
  • Find out why Novartis see blockchain technologies having the potential to hugely improve third party risk management
  • Learn how agreed and standardised digital identifiers can reduce admin and streamline processes across the entire supply chain
  • Discover where else blockchain is starting to make a real impact on workflows in drug and treatment lifecycles

Marco Cuomo Manager, Applied Technology Innovation Novartis

Daniel Fritz Domain Architect Supply Chain & External Supply Novartis


XR & digital health – the next frontier

  • Get a high-level overview of the technologies and hardware out there now… and what’s coming next
  • Hear about current capabilities and near-term evolution of XR across enterprise
  • Explore some use cases & initiatives in operation across the pharma & healthcare including in R&D, behavioural health, training & education, remote collaboration, patient care and more
  • Learn about XR integration with other tech i.e. Blockchain, AI, Machine Learning, Eye Tracking and what this means for the adoption of the technologies

Amy Peck Founder & CEO EndeavorVR


How virtual reality is impacting the treatment of mental health

  • Understand the very real power of virtual reality (VR) to help treat a whole range of mental health conditions
  • Discover how it's already supporting the treatment of depression, phobias and other anxiety disorders
  • Find out how both therapists and patients can benefit from using VR to better choose effective treatment pathways
  • Hear how VR is being best used as a companion treatment alongside traditional medicines and the results clinicians are seeing

Xavier Palomer CEO Psious


Why advances in immunotherapy is heralding an age of truly personalised cancer treatment

  • Get insight on how new developments in targeted cell therapy have the potential to transform cancer treatment
  • Where are the primary risks? And what’s being done to minimize these and drive improved outcomes?
  • Where are we seeing the biggest breakthroughs – which cancer types, which patient types?


Inside out innovation: How Ferring is creating the next generation of business models and solutions by pioneering with an eco-system of innovative start-ups & tech players

  • Understand how your company can leapfrog into disruptive business models
  • To succeed, you must first fail: grasp how commercial innovation and positive failure are intrinsically linked
  • Explore how to structure the organisation to develop commercial agility

Haider Alleg Global Head of Digital Excellence Ferring

A new confidence in clinical innovation


Say yes! Overcome perceived risks for new types of trial with unproven ROI

  • Feel the fear and do it anyway: How to determine an appropriate risk tolerance for pursuing unmet needs and betting on approval
  • Rework organisational responsibilities to break deadlocks, empower and support Clin Ops, and ensure trials are reimagined in a futureproof manner

Mohammed Ali Global Head Digital Development, Global Clinical Operations Boehringer Ingelheim

Bert Hartog Senior Director, Clinical Innovation Janssen


LEO Innovation Lab: how a new clinical paradigm was created within a 110-year old company

  • How an open-minded approach to evidence enabled the identification of new subtypes of diseases through RWD
  • A guide to successful remote clinical trials in dermatology and how this was done in an Innovation Lab, separate to the mothership
  • Simplicity is key: avoid complexity on the most complex treatments and ensure your trials don’t add to the EHR burden through careful management

Rasmus Hogreffe Head of Virtual Clinical Trials LEO Innovation Lab

Go big or go home: prioritize scalability


Move from local pilot to worldwide trial

  • Examine methods for evaluating pilots and determine resources for scaling
  • Get awesome technology into remote locations: what you need in terms of global support infrastructure to drive a high adoption rate


Build a collaborative development framework for novel digital endpoints

  • To put the patient at the centre, determine how to define meaningful novel digital endpoints
  • Leverage existing guidance and processes and account for technical complexity in endpoint development
  • How a collaborative business model enables you to fast-track development and improve reliability
  • An assessment of fit-for-purpose technology that enables quick adoption without losing flexibility

Kai Langel Director, R&D Operations Innovation Janssen


Interoperability – both technology and people – as the greatest win for patient care

  • Stop paralyzing your research – find ways to reduce the interoperability burden from the outset and get closer to the universal HER
  • Trust as the key currency for building an alliance for data sharing and efficient coalition between multiple institutions
  • How to work with regulators – understand the FDA/EMA mindset, build alliances and secure acceptance for your innovations

Joy Bhosai Chief of Digital Health & Strategy Duke University


Digital recruitment with depth – how Novartis will increase trial participation

  • A new approach to trial recruitment which combines broad channels/materials with specific identification of suitable candidates
  • Detaching physical location from eligibility – enabling through technology
  • How a multichannel approach can be used to build trust and ensure a patient centric trial design

Sam Hariry Head of Clinical Strategy & Operations Novartis

Data, defragmented


How to create virtual trial participants

  • Understand the rationale and criteria for building virtual trial cohorts and compensate for lack of participant data
  • A journey through Ipsen’s process in building evidence with translational approaches, mixing RWE and clinical data, adding genomics, metabolomics and validating with the FDA
  • Use this aggregated information and high-quality algorithms to create predictions and best target identification

Stephane Orssaud R&D Biometry Innovation Director Ipsen


End to end clinical trials using patient records: run randomised trials entirely based on real world data

  • Hear how the CPRD are combing PRO & EHR to assess clinical effectiveness purely from RWD sets

Janet Valentine Director of the CPRD CPRD

Clinical leadership, organisational reform and new trial models


Patient involvement from the beginning, not the endpoint

  • How to ensure the patient perspective is always the driver, not the follower, despite the increasing prioritization of technological innovation
  • Identify the gaps in your understanding that you need to fill in order to ensure you have identified stage-gate specific goals that need to be informed by the patient perspective
  • A look at Biogen’s 5-step process used to develop a PFDD strategy, with examples of key questions and methodology/tools

Isabela Niculae R&D Portfolio Transformation Leader Biogen


Trials@Home: Reshaping Remote Digital Clinical Trials in Europe

  • How to analyse previous centralised/RDC/hybrid trials and develop best-practice protocols to enable a pan-EU pilot
  • Ensure smart, complaint roll-out of RDCT’s by forging strong partnerships with HCPs, participants, regulators and other relevant stakeholders
  • Scanning, characterizing available technologies to support RDCTs and applying design thinking processes to create a robust, end-to-end technology package

Kai Langel Director, R&D Operations Innovation Janssen


PANEL: The new clinical ecosystem – who will be disrupted, who will be displaced?

  • Gain market maturity by comprehending today’s spectrum of different approaches – from centralized PIs to virtual and remote networks. An objective perspective on the landscape of approaches and where they’re headed
  • Why new marketplaces and automation could disrupt CROs whilst new data, could disrupt pharma development organizations
  • How technology can disrupt the fundamental nature of trial participation for patients and likely pathways to progression

Craig Lipset Former Head of Clinical Innovation Formerly Pfizer

Michelle Shogren Director of Innovation - Pharma R&D Clinical Operations Bayer


Reality check! A practical methodology for bringing hybrid virtual trials to life

  • When high technology expectations combine with standard of care practises – how to bridge the gap
  • Co-develop technology models with Sites and Primary Care and shift the paradigm with use of Home Health, eCOA, eConsent, EDC etc
  • Manage remote/direct-to-patient assessments and how to bring in effective measurement/learning processes

Adama Ibrahim Associate Director, Performance Operational Capabilities, Global Clinical Operations Biogen


The Clinical Entrepreneur: how agility will be a necessity for successful digitization of the trial

  • Examples of Lundbeck’s efforts to rewrite clinical planning & execution through a faster, iterative, learning model
  • Man vs machine – understand how to balance resources in a smarter way
  • A fresh perspective on the steps required to get your trial from idea to infinity

Mads Dalsgaard Senior Vice President, Head of Experimental Medicine & Clinical Development Lundbeck

The whole world’s a trial


The questions you need to ask your 9-million-patient advisory board

  • Electronic medical records and claims data have known blind spots, so should be supplemented with direct patient feedback. Explore how the deeply-phenotyped, engaged 23andMe community can power stronger patient insights
  • How to have a more robust dialogue with target patient populations through validated data collection and direct-to-consumer expertise
  • Examples of a more rigorous approach to market sizing, unmet need, protocol burden, operational feasibility and gathering consumer insights – and the impact with health stakeholders

Shawn Tedman Director, Clinical Trials Business 23andME


Build a global digital support network that enables full rollout in multiple territories

  • Find technology providers who can develop and distribute medicines, IoT-type devices, sensors, variables into people’s homes in a global setting
  • Build a coalition of partners that ensure your trials deliver effectiveness in new regions

Bert Hartog Senior Director, Clinical Innovation Janssen

A Bold New World


Activating the Ecosystem around DTx: a vital activity for enabling adoption

  • Why education and awareness are critical for every DTx initiative - the last mile
  • Importance of demonstrating the health economics of DTx - country stakeholder groups are champions
  • Proposing the investigation of a Joint European Assessment Framework for DTx

Jessica Shull European Lead Digital Therapeutics Alliance


Exploring the physician and patient perspective on DTx: Is it in their consciousness?

  • Get an exclusive view into the physician’s perspective on DTx across 21 countries (via Ipsos’ Digital Doctor 2020 study)
  • Explore what “informed” patients think of the potential of DTx and how this effects their drivers and barriers to adoption (via Ipsos’ Patient Influencers study, in partnership with WEGO Health)

Reena Sangar Global Head, Connected Health Ipsos


Partnership in Practice: Happify and Sanofi’s new platform for patient engagement and quality of life

  • Why addressing key co-morbidities for individuals living with multiple sclerosis (MS), including depression and anxiety, digitally, opens new doors for Sanofi
  • Understand the key synergies such as relationships with large US health plans and employers
  • How the partnership conducted a global pilot study across 50 countries through social media, leveraging their existing consumer digital therapeutic platform

Bozidar Jovicevic VP, Global Head of Digital Therapeutics Sanofi

Chris Wasden Head of HappifyDTx Happify Health

Regulatory Questions, Interpreted and Answered


Get approved: understand Medical Device Regulations (MDR) and requirements from Notified Bodies

  • Balance evolving products with the rigour required for a safe regulatory environment
  • Examine the Notified Body’s interpretation and how to shepherd your product through to market

Robert Madjino Director, Clinical Assessment TUV SUD


Germany's Law for Digital Health Reimbursement (DVG)

  • Understand the inner workings of Germany’s ground-breaking policy and new thoughts on how to treat patients
  • Learn about the criteria set by BfArM and what the medical community is thinking

Henrik Matthies Managing Director Health Innovation Hub


Panel: The pathway to prescriptions: navigate the varying national regulatory & reimbursement criteria in France, Belgium and the UK

  • Examine the plans and intentions of each of the national institutions currently reimbursing DTx
  • Gain true comprehension of what has led us to this point and the nuances of how reimbursement is projected over the next 5 years

Steven Vandeput Advisor Extramuros & Digital Health beMedTech

Chris Chesters Senior Scientific Adviser NICE

Megan Coder Executive Director Digital Therapeutics Alliance


Panel: Getting paid: how leading companies have journeyed to reimbursement across the EU

  • Hear the twists and tales as early trailblazers have sought to become viable businesses

Rossana Alessandrello Coordinator of Innovation & Value Based Procurement AQuAS

Maryne Cotty-Eslous Founder Lucine

Lloyd Humphreys Head of Europe SilverCloud Health

Adam Kirk Clinical Director My mHealth

The Evolution of Pharma


Panel: Work with the patient as a partner to co-create and co-evolve digital therapies

  • Establish a patient-first mindset and understand the best ways to facilitate patient involvement in your development
  • Incorporate the science of behaviour change to provide greater traction and outcomes for patients
  • Explore ways to raise digital adherence and better patient outcomes

David Verdura Chief Operating Officer Curelator

Enric Barba Ibañez Patient & Digital Health Advocate

Door Vonk Founder Tired of Cancer

Olivier Jarry President & Cheif Commerical Officer DarioHealth


New standards of care that enable pharma companies to commercialize digital health solutions and allow HCPs to offer more

  • Examine differentiated business models and best practice for forward-thinking pharmaceutical companies
  • A guide to solution-oriented commercialization models that encourage internal and external stakeholders to drive uptake
  • How the magic formula [Science + Data + Technology + Evidence = patient-centric medicine] works in DTx

Anish Shindore VP, Head of Digital Acceleration - DTx Sanofi


Panel: Harness the DTx data opportunity: insight from gathering RWE on the front lines

  • How to develop an effective feedback loop to ensure your product evolution is based on solid evidence
  • Are you using data well? Understand the multiple utilities of good data stewardship in seeking patient access and value
  • Determine the outcomes-based agreements you may be able to forge through exemplary data

Austin Speier Chief Strategy Officer Click Therapeutics

Roundtable exercise


Design a DTx trial with stakeholders

  • Your task is to design a successful clinical study in a small group
  • Work with developers and clinical experts on a team, putting a new trial together

Carmen Rios VP International Limbix